PMA device
Monovisc
Anika Therapeutics, Inc. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Feb 25, 2014, newest Jan 9, 2020Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
772
Naming "Monovisc"
MAUDE reports
166
Brand "Monovisc", since 2015
PubMed studies
17
Mentioning "Monovisc"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Monovisc
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- MonoviscPMA supplement
P090031-S009 · Decided Jan 9, 2020 · 174 days after receipt · Normal 180 Day Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
- MONOVISCPMA
P090031 · Decided Feb 25, 2014 · 1,519 days after receipt
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Monovisc", any status and sponsor, newest update first.
- Hyaluronic Acid Barrier in ParotidectomyNot yet recruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT07941011 · 20 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 31, 2029
Device: Axoguard HA+ Nerve Protector · For: Parotidectomy, Patient-reported Outcomes; Parotid Cancer; Parotid Gland Tumor and 2 more
- Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal WomenCompleted
Perfect Care DistributionNot on our public-company list
NCT07932990 · 252 participants · Start Mar 7, 2025 · Primary completion Apr 22, 2026
Device: Halova vaginal ovules · For: Genitourinary Syndrome of Menopause (GSM); Vaginal Dryness; Vulvo Vaginal Atrophy (VVA)
Sites: Arad, Romania
- Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human SkinActive, not recruiting
University of MichiganAcademic, hospital or other
NCT06195605 · 15 participants (planned) · Start May 9, 2024 · Primary completion Nov 2027
Device: Restylane-L; Vehicle · For: Photoaging
Sites: Ann Arbor, Michigan
769 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Monovisc", and for the whole product code for context.
This brand
166 reports: 39 malfunction, 116 injury, 7 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- MonoviscInjury
3007093114-2026-00028 · Received Sep 21, 2026 · Event dated Sep 8, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Pain; Joint effusion
- MonoviscInjury
3007093114-2026-00027 · Received Sep 15, 2026 · Event dated Jun 12, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Joint effusion
- MONOVISCInjury
MW6002198 · Received Sep 11, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: High Blood Pressure/ Hypertension
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Monovisc"[tiab]. The summary above synthesizes these.
- A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee.
Peck J, Slovek A, Miro P, et al. · Orthop Rev (Pavia) · 2021Review
- Intraarticular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others?
Webner D, Huang Y, Hummer CD · Cartilage · 2021Research Support, Non-U.S. Gov't, Review
- Pharmaceutical approval update.
Goldenberg MM · P T · 2014
- Single-injection hyaluronic acid treatment demonstrates non-inferiority in the relief of symptomatic knee osteoarthritis: A randomized double-blind, multi-center controlled study.
Ruosi C, Longo UG, Giordan N, et al. · Osteoarthr Cartil Open · 2026
- The Effect of a Single Hyaluronic Acid Injection in Ankle Arthritis: A Prospective Cohort Study.
Jantzen C, Ebskov LB, Andersen KH, et al. · J Foot Ankle Surg · 2020
- Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial.
Hangody L, Szody R, Lukasik P, et al. · Cartilage · 2018Multicenter Study, Randomized Controlled Trial
- Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial.
Petterson SC, Plancher KD · Knee Surg Sports Traumatol Arthrosc · 2019Multicenter Study, Randomized Controlled Trial
- A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid.
Nicholls M, Manjoo A, Shaw P, et al. · Adv Ther · 2018Research Support, Non-U.S. Gov't
- The Potential Role of Zilretta in Reducing Intra-Articular Effusions.
Maloney K, Colon T · Ochsner J · 2025Case Reports
- Risk of Severe Acute Localized Reactions for Different Intraarticular Hyaluronic Acid Knee Injections in a Real-World Setting.
Ong KL, Farr J, Gudeman AS, et al. · Cartilage · 2021Research Support, Non-U.S. Gov't
- Comparison of the 3 Different Injection Techniques Used in a Randomized Controlled Study Evaluating a Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) for Osteoarthritis of the Knee: A Subgroup Analysis.
McCormack R, Lamontagne M, Vannabouathong C, et al. · Clin Med Insights Arthritis Musculoskelet Disord · 2017
- Two new intra-articular injections for knee osteoarthritis.
Med Lett Drugs Ther · 2018
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
- Orthovisc Sodium HyaluronateAnika Therapeutics, Inc. · PMA 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.